
The new drug is similar to two other cyclin-dependent kinase (CDK) 4/6 inhibitors, but it also has some distinguishing qualities.
FDA Approvals
This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.
Leave a Reply